Compare AAME & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAME | ATOS |
|---|---|---|
| Founded | 1968 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 36.2M |
| IPO Year | 1995 | 2010 |
| Metric | AAME | ATOS |
|---|---|---|
| Price | $1.75 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 14.8K | ★ 270.6K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $188,227,000.00 | $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.64 | ★ N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $1.59 | $0.53 |
| 52 Week High | $3.71 | $7.56 |
| Indicator | AAME | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 37.67 | 18.41 |
| Support Level | $1.59 | $0.63 |
| Resistance Level | $3.16 | $6.18 |
| Average True Range (ATR) | 0.10 | 0.20 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 43.33 | 4.67 |
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.